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Dear Editor,
Vitamin D supplementation in patients who suffer from
sarcoidosis and are simultaneously at high risk of develop-
ing glucocorticoid-induced osteoporosis can represent a
dilemma in clinical decision making. To illustrate this
critical situation, we report the case of a 53-year-old woman
with renal sarcoidosis, chronic hepatitis C, and an HIV
infection effectively controlled with highly active anti-ret-
roviral therapy. She was admitted to the emergency room
due to progressive excessive fatigue, generalized weakness,
lethargy, and headache. Physical examination revealed a
reduced general condition, signs of hypovolemia, and gen-
eralized muscular weakness without focal signs. Regarding
her medical history, sarcoidosis was diagnosed 2 years
earlier. This disease predominantly affected the kidneys,
manifesting itself as an interstitial granulomatous nephritis
(Fig. 1). Liver and retinae were affected to a lesser extent,
and lungs were free from the disease. Since the diagnosis,
she had been treated with glucocorticoids and was taking
25 mg of prednisone per day at the time of admission.
Although the patient was additionally taking 75 mg of
azathioprine per day, it was impossible to reduce the pred-
nisone dose. Despite the continuous immunosuppressive
therapy, sarcoidosis had already led to a significant renal
impairment including a moderate proteinuria (1.5 g/day)
and a reduced glomerular filtration rate (40 mL/min). Dur-
ing the previous 2 years, the patient occasionally received
vitamin D supplementation based on 25(OH)D3 serum
levels. Two weeks before the admission to the hospital,
25(OH)D3 serum concentration was measured at 18 ng/mL
(47 nmol/L), for which the patient received a single oral
dose of 300.000 IU cholecalciferol. At this time, serum
calcium was 2.41 mmol/L (normal, 2.15–2.55 mmol/L).
Laboratory analysis at the time of admission revealed serum
calcium 3.42 mmol/L, serum phosphate 1.88 mmol/L
(normal, 0.8–1.4 mmol/L), and serum creatinine 299 lmol/L.
Serum levels of 25(OH)D3 and 1,25-dihydroxyvitamin D
[1,25(OH)2D3] were 52.4 ng/mL (=130 nmol/L) and
119 pmol/l (normal, 48–160 pmol/L), respectively. In view
of these results, we diagnosed severe hypercalcemia, which
we traced back to the single high dose of cholecalciferol.
Other common causes of hypercalcemia were excluded.
The patient was treated with stringent hydration (approx.
3000 mL sodium-chloride 0.9 %/day), which resulted in a
slow decrease in serum calcium (2.47 mmol/L) and creati-
nine (212 lmol/L). The patient recovered from the clinical
symptoms within six days and was discharged from hospital.
One week later, serum calcium rebounded to 2.76 mmol/L.
With a single dose of intravenous pamidronate (30 mg),
serum calcium fell in the normal range. 25(OH)D3 and
1,25(OH)2D3 serum levels remained at the normal range
(32 ng/mL and 49 pmol/L, respectively) up to four months
after the hospitalization.
The patient’s clinical condition presented a dilemma in
decision making. Indeed, the high risk of glucocorticoid-
induced osteoporosis is normally an indication to maintain
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25(OH)D3 serum levels C30 ng/mL, according to current
international guidelines [1, 2]. However, levels of
25(OH)D3 C30 ng/mL can already result in vitamin
D-related toxicity in sarcoidosis patients [3], as it was
the case with our patient, although—theoretically—the
administration of glucocorticoids should have sufficiently
suppressed the expression of the inducible form of the
1a-hydroxylase [3]. In conclusion, our case suggests a
cautious use of vitamin D supplementation, especially of
single high doses, as well as a close monitoring of its
effects in patients with granulomatous diseases, even in the
presence of glucocorticoids.
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Fig. 1 Sarcoidosis interstitial granulomatous nephritis. FAOG-stain-
ing, 9200. A granuloma is encircled
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